期刊
CURRENT PHARMACEUTICAL DESIGN
卷 27, 期 13, 页码 1597-1607出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612827666210311141512
关键词
Tocilizumab; COVID-19; SARS-CoV2; tocilizumab; monoclonal antibodies; interleukin-6; cytokines
Tocilizumab is being investigated as a potential treatment for severe COVID-19, with evidence suggesting it may help reduce immune-induced organ damage caused by SARS-CoV-2 infection. However, the efficacy and safety of tocilizumab for COVID-19 remain controversial, with ongoing trials and data analysis needed to provide more clarity for future outbreaks.
Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment for severe coronavirus-induced disease 2019 (COVID-19). Despite the lack of direct antiviral effects, tocilizumab could reduce the immune-induced organ damage caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection. Until recently, most reports on tocilizumab for COVID-19 included a limited number of patients, preventing an overall evaluation of its efficacy and safety for this specific condition. Therefore, we reviewed the literature regarding the physiopathological rationale of tocilizumab for COVID-19 and its outcomes. We searched the MEDLINE database with the string (SARS-CoV-2 OR coronavirus OR COVID-19 OR MERS- cov OR SARS-cov) AND (IL-6 OR interleukin 6 OR tocilizumab). While the scientific rationale supporting tocilizumab for COVID-19 is solid, the evidence regarding the outcomes remains controversial. Available data and results from ongoing trials will provide useful information in the event of new COVID-19 outbreaks or future pandemics from different coronaviruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据